Based on our findings, we propose that calcitriol exerts its renoprotective effects in patients with DKD through multiple pathways: 1) direct anti-inflammatory effects through IL-6 inhibition, 2) protection against tubular injury, as evidenced by reduced KIM-1 levels, and 3) potential podocyte stabilization through the modulation of inflammatory pathways. This evidence concerns the gene HAVCR1 and diabetic kidney disease.